Skip to main content
Premium Trial:

Request an Annual Quote

Oops...

NIH Director Francis Collins got ahead of himself this week when he sent his staff a memo announcing the official creation of the National Center for Advancing Translational Science, reports ScienceInsider's Jocelyn Kaiser. As it turns out, however, Collins had to retract the email an hour after sending it when he was told that President Barack Obama hadn't yet signed off on the bill. "The omnibus appropriations bill for FY2012 passed by Congress and signed into law by President Obama today includes provisions that formally establish the National Center for Advancing Translational Sciences (NCATS) as a new component of the NIH," Collins' first email read.

That email was soon followed by another. "The President signed a Continuing Resolution until December 23, so nothing is finalized until we have a signed bill. We apologize for any confusion," he later wrote.

The mistake is the latest "glitch in the saga" of NCATS, Kaiser says. For the past year, many in the scientific community have argued that NCATS is the wrong way to go, and that Collins "was ramming NCATS through without adequate discussion," Kaiser adds. "For the many critics of the NCATS reorganization, the premature memo rubbed salt in their wounds."

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.